Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PIK3CA amplification

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

PIK3CA mutation (108)

PIK3CA H1047R (45)

PIK3CA E545K (26)

PIK3CA E542K (10)

BRAF V600E + PIK3CA mutation (4)

EGFR mutation + PIK3CA mutation (4)

PIK3CA E545 (4)

PIK3CA H1047 (4)

PIK3CA K111N (4)

PIK3CA E542 (3)

PIK3CA E546 (3)

PIK3CA H1047L (3)

PIK3CA M1043I (3)

PIK3CA mutation + PTEN mutation (3)

PIK3CA wild-type (3)

EGFR T790M + PIK3CA H1047R (2)

ER negative + PIK3CA H1047R (2)

HER-2 V777L + PIK3CA H1047R (2)

PIK3CA C420R (2)

PIK3CA E545A (2)

PIK3CA N345K (2)

PIK3CA Q75E (2)

PIK3CA mutation + ESR1 mutation (2)

PIK3CA mutation + KRAS mutation (2)

TP53 T175H + PIK3CA H1047R (2)

TP53 mutation + PIK3CA mutation + CD74 mutation (2)

ALK rearrangement + PIK3CA mutation (1)

ALK rearrangement + TP53 R175H + EGFR A839V + PI3KCA mutation (1)

EGFR L858R + PIK3CA H1047R + PIK3CA E545K (1)

EGFR T790M + PIK3CA Mutation (1)

EGFR exon 19 mutation + EGFR C797S + PIK3CA mutation (1)

HR positive + PIK3CA H1047R (1)

HR positive + PIK3CA H1047R + ER D538G (1)

HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G (1)

IDH1 R132C + PIK3CA E545K + IDH2 R172K (1)

PIK3CA D350G (1)

PIK3CA E110K (1)

PIK3CA E453K (1)

PIK3CA E542Q (1)

PIK3CA E545G (1)

PIK3CA E545X (1)

PIK3CA G1049R (1)

PIK3CA G1049R + AKT1 E17K (1)

PIK3CA G106_108del (1)

PIK3CA H1047R + PIK3CA D959N + ER E380Q (1)

PIK3CA H1047X (1)

PIK3CA I391M (1)

PIK3CA K944N (1)

PIK3CA K966E (1)

PIK3CA N345K + PIK3CA N1044K (1)

PIK3CA P449T (1)

PIK3CA Q546 (1)

PIK3CA Q546K (1)

PIK3CA R38C (1)

PIK3CA V955G (1)

PIK3CA mutation + AKT1 mutation + PTEN mutation (1)

PIK3CA mutation + EP300 mutation (1)

PIK3CA mutation + ER mutation (1)

PIK3CA mutation + FGFR2 rearrangement (1)

PIK3CA mutation + HRAS mutation (1)

PIK3CA mutation + PTEN mutation + KRAS mutation (1)

PIK3CA mutation + TERT promoter mutation (1)

PIK3CA mutation + TTN mutation + IDH2 mutation (1)

PIK3CA wild-type + KRAS wild-type (1)

PIK3CA wild-type + PTEN wild-type (1)

PIK3CA Q546R (1)

HER-2 negative + HR positive + PIK3CA exon 20 mutation (0)

HER-2 negative + HR positive + PIK3CA exon 7 mutation (0)

HER-2 negative + HR positive + PIK3CA exon 9 mutation (0)

HER-2 negative + HR positive + PIK3CA mutation (0)

PIK3CA G542L (0)

PIK3CA mutation (108)

PIK3CA H1047R (45)

PIK3CA E545K (26)

PIK3CA E542K (10)

BRAF V600E + PIK3CA mutation (4)

EGFR mutation + PIK3CA mutation (4)

PIK3CA E545 (4)

PIK3CA H1047 (4)

PIK3CA K111N (4)

PIK3CA E542 (3)

PIK3CA E546 (3)

PIK3CA H1047L (3)

PIK3CA M1043I (3)

PIK3CA mutation + PTEN mutation (3)

PIK3CA wild-type (3)

EGFR T790M + PIK3CA H1047R (2)

ER negative + PIK3CA H1047R (2)

HER-2 V777L + PIK3CA H1047R (2)

PIK3CA C420R (2)

PIK3CA E545A (2)

PIK3CA N345K (2)

PIK3CA Q75E (2)

PIK3CA mutation + ESR1 mutation (2)

PIK3CA mutation + KRAS mutation (2)

TP53 T175H + PIK3CA H1047R (2)

TP53 mutation + PIK3CA mutation + CD74 mutation (2)

ALK rearrangement + PIK3CA mutation (1)

ALK rearrangement + TP53 R175H + EGFR A839V + PI3KCA mutation (1)

EGFR L858R + PIK3CA H1047R + PIK3CA E545K (1)

EGFR T790M + PIK3CA Mutation (1)

EGFR exon 19 mutation + EGFR C797S + PIK3CA mutation (1)

HR positive + PIK3CA H1047R (1)

HR positive + PIK3CA H1047R + ER D538G (1)

HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G (1)

IDH1 R132C + PIK3CA E545K + IDH2 R172K (1)

PIK3CA D350G (1)

PIK3CA E110K (1)

PIK3CA E453K (1)

PIK3CA E542Q (1)

PIK3CA E545G (1)

PIK3CA E545X (1)

PIK3CA G1049R (1)

PIK3CA G1049R + AKT1 E17K (1)

PIK3CA G106_108del (1)

PIK3CA H1047R + PIK3CA D959N + ER E380Q (1)

PIK3CA H1047X (1)

PIK3CA I391M (1)

PIK3CA K944N (1)

PIK3CA K966E (1)

PIK3CA N345K + PIK3CA N1044K (1)

PIK3CA P449T (1)

PIK3CA Q546 (1)

PIK3CA Q546K (1)

PIK3CA R38C (1)

PIK3CA V955G (1)

PIK3CA mutation + AKT1 mutation + PTEN mutation (1)

PIK3CA mutation + EP300 mutation (1)

PIK3CA mutation + ER mutation (1)

PIK3CA mutation + FGFR2 rearrangement (1)

PIK3CA mutation + HRAS mutation (1)

PIK3CA mutation + PTEN mutation + KRAS mutation (1)

PIK3CA mutation + TERT promoter mutation (1)

PIK3CA mutation + TTN mutation + IDH2 mutation (1)

PIK3CA wild-type + KRAS wild-type (1)

PIK3CA wild-type + PTEN wild-type (1)

PIK3CA Q546R (1)

HER-2 negative + HR positive + PIK3CA exon 20 mutation (0)

HER-2 negative + HR positive + PIK3CA exon 7 mutation (0)

HER-2 negative + HR positive + PIK3CA exon 9 mutation (0)

HER-2 negative + HR positive + PIK3CA mutation (0)

PIK3CA G542L (0)

›

PIK3CA amplification	HER2 Positive Breast Cancer	PIK3CA amplification	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA amplification	Chordoma	PIK3CA amplification	Chordoma	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	alpelisib + tipifarnib Sensitive: C3 – Early Trials alpelisib + tipifarnib Sensitive : C3	alpelisib + tipifarnib Sensitive: C3 – Early Trials alpelisib + tipifarnib Sensitive : C3
PIK3CA amplification	Prostate Cancer	PIK3CA amplification	Prostate Cancer	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
PIK3CA amplification	Non Small Cell Lung Cancer	PIK3CA amplification	Non Small Cell Lung Cancer	GDC-0941 Sensitive: D – Preclinical GDC-0941 Sensitive : D	GDC-0941 Sensitive: D – Preclinical GDC-0941 Sensitive : D
PIK3CA amplification	Gastric Cancer	PIK3CA amplification	Gastric Cancer	alpelisib Sensitive: D – Preclinical alpelisib Sensitive : D	alpelisib Sensitive: D – Preclinical alpelisib Sensitive : D
PIK3CA amplification	HER2 Positive Breast Cancer	PIK3CA amplification	HER2 Positive Breast Cancer	LX-086 Sensitive: D – Preclinical LX-086 Sensitive : D	LX-086 Sensitive: D – Preclinical LX-086 Sensitive : D
PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D
PIK3CA amplification	Lung Cancer	PIK3CA amplification	Lung Cancer	PI3K inhibitor + EZH2 inhibitor Sensitive: D – Preclinical PI3K inhibitor + EZH2 inhibitor Sensitive : D	PI3K inhibitor + EZH2 inhibitor Sensitive: D – Preclinical PI3K inhibitor + EZH2 inhibitor Sensitive : D
PIK3CA amplification	Lung Cancer	PIK3CA amplification	Lung Cancer	EZH2 inhibitor Sensitive: D – Preclinical EZH2 inhibitor Sensitive : D	EZH2 inhibitor Sensitive: D – Preclinical EZH2 inhibitor Sensitive : D
PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	palbociclib + alpelisib Sensitive: D – Preclinical palbociclib + alpelisib Sensitive : D	palbociclib + alpelisib Sensitive: D – Preclinical palbociclib + alpelisib Sensitive : D